ABS-201
- Phase 1 injection · Prolactin-receptor antibody · AbSci · trial NCT07317544 · sponsor targets early 2027 for full phase 1 data (said Aug 2026)
Antibody that blocks the prolactin receptor, in Phase 1 for androgenetic alopecia
ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial for the treatment of androgenic alopecia and endometriosis. It is taken by subcutaneous injection. ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. ABS-201 is under development by Absci.
Read “ABS-201” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 1
All on OpenAlex →Posts 14
- Everything you ever wanted to know about Pelage Pharma's PP405: how it works and what to expect
- Finally, some real breakthroughs. A comparison of the two leading baldness treatments: PP405 versus ABS-201
- Prolactin the Cause of Hair Loss? ABS-201 the Cure?
- Anyone following ABS-201: AI-designed monoclonal antibody that blocks the prolactin receptor (PRLR)?
- Interview with ABSCI CEO: Think of this as "The Ozempic of Hair Regrowth".
- $20,000 reimbursement to participate in a Hair Loss Clinical Trial (in Australia) that could grow back your hair and reverse grey hair if successful.
- Now That PP405 Hype is Gone What is Everyone Coping with as the Next Cure?
- What about Berberine as a 5-alpha-reductase and androgen receptors inhibitor ?
- HopeMed (Hmi115) is pissed at Absci (Abs-201)
- MPB - Has anyone else seen this video on ABS-201?
- PP-405 Phase 2/3 study has begun
- Ensayo ABS-201 - Qué debería saber antes de empezar
- Upcoming and current hair growth stimulants (2026)
- Dutasteride 0.5 mg 3 times a week 7 month transformation.